PAVmed

PAVmed P/TBV

The Price to Tangible Book Value (P/TBV) of PAVmed (PAVM) as of Nov 22, 2026 is 0.33. In the previous year, Price to Tangible Book Value (P/TBV) was -4.45 — a change of -107.35% (higher).

P/TBV

0.33

YoY

-107.35%

Last updated:

Price to Tangible Book Value (P/TBV) of PAVmed is 2025 0.33 . Price to Tangible Book Value (P/TBV) of PAVmed was 2024 -4.45 . It decreases by -107.35% higher compared to the previous year.

The PAVmed P/TBV history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

P/TBV
Date
P/TBV
Jan 1, 2018
-4.80 USD
Jan 1, 2019
-2.91 USD
Jan 1, 2020
5.86 USD
Jan 1, 2021
0.01 USD
Jan 1, 2022
-0.85 USD
Jan 1, 2023
-0.20 USD
Jan 1, 2024
-4.45 USD
Jan 1, 2025
0.33 USD
The PAVmed P/TBV history
YEARP/TBVYoY
0.33-107.35%
-4.45+2,114.63%
-0.20-76.24%
-0.85-15,990.69%
0.01-99.91%
5.86-301.68%
-2.91-39.47%
-4.80+23.06%
-3.90-88.80%
-34.82-298.68%
17.53+25.38%
13.98—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PAVmed Stock analysis

What does PAVmed do? PAVmed, Inc. generates revenue through the development and commercialization of medical devices including PortIO, a vascular access device without central venous system access or indwelling intravascular components, and CarpX, a percutaneous device for carpal tunnel syndrome treatment. The company also offers NextCath, a self-anchoring catheter eliminating the need for suturing or traditional anchoring methods, and DisappEAR, antibiotic-eluting resorbable ear tubes utilizing aqueous silk technology. Additional products include NextFlo, a disposable infusion system with variable flow resistors, and Caldus, a disposable tissue ablation device. Medical device companies and healthcare providers purchase these products for patient treatment and surgical procedures. The firm's product portfolio targets specific medical needs such as vascular access, orthopedic procedures, and ear treatments. PortIO serves patients requiring long-term vascular access without traditional central line risks. CarpX addresses carpal tunnel syndrome through minimally invasive procedures. DisappEAR provides a solution for ear tube insertion using resorbable technology, reducing the need for follow-up surgeries. NextCath streamlines catheter placement in medical settings. PAVmed's commercial strategy focuses on medical device companies and healthcare providers seeking innovative solutions for vascular access, orthopedic interventions, and ear care. The company's products are designed to improve patient outcomes while reducing procedural complexity and costs. By leveraging proprietary technologies like aqueous silk for DisappEAR, PAVmed differentiates its offerings in the medical device market. PAVmed is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PAVmed stock

Price to Tangible Book Value (P/TBV) of PAVmed is 0.33 in 2025.

Price to Tangible Book Value (P/TBV) of PAVmed changed from -4.45 to 0.33, representing a -107.35% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Price to Tangible Book Value (P/TBV) PAVmed since 2006 – with annual values, charts, and detailed analysis.

P/TBV compares the stock price to tangible book value per share, excluding goodwill and intangibles. It provides a conservative asset-based valuation.

To evaluate Price to Tangible Book Value (P/TBV)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Price to Tangible Book Value (P/TBV).

A 'good' varies by industry and company stage. On Eulerpool, you can compare Price to Tangible Book Value (P/TBV)'s PAVmed with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — PAVmed

All Key Metrics — PAVmed